Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.53 |
| ▸ | SKP1 | P63208 | 2/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 9/20 | 0.48 |
| ▸ | HTR1D | P28221 | 9/20 | 0.48 |
| ▸ | HTR1B | P28222 | 9/20 | 0.48 |
| ▸ | GBA1 | P04062 | 2/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430227 | 0.96 | CYP2C9 (0.52) | CKS1BSKP1SKP2CYP2C9NCF1 | |
| SCHEMBL6521227 | 0.86 | CKS1B (0.52) | CKS1BSKP1SKP2GBA1PDE10A | |
| SCHEMBL425806 | 0.83 | BACE1 (0.51) | CKS1BSKP1SKP2NCF1GBA1 | |
| SCHEMBL5379011 | 0.82 | GBA1 (0.49) | CKS1BSKP1SKP2GBA1 | |
| SCHEMBL5523102 | 0.82 | NCF1 (0.72) | CKS1BSKP1SKP2NCF1GBA1 | |
| SCHEMBL431774 | 0.81 | GBA1 (0.48) | CKS1BSKP1SKP2GBA1 | |
| SCHEMBL429714 | 0.81 | GBA1 (0.48) | CKS1BSKP1SKP2GBA1PDE10A | |
| SCHEMBL428233 | 0.81 | GBA1 (0.48) | CKS1BSKP1SKP2NCF1GBA1 | |
| SCHEMBL4178112 | 0.81 | NCF1 (0.59) | CYP2C9NCF1HTR1AHTR1DHTR1B | |
| SCHEMBL20140758 | 0.81 | CKS1B (0.60) | CKS1BSKP1SKP2PDE10AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | CKS1B 3396/4885SKP1 2121/4885SKP2 4321/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | CKS1B 3271/4885SKP1 1450/4885SKP2 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.